Pharmaceutical companies are navigating a changing landscape defined by GLP-1 innovation, AI-supported drug discovery, and evolving healthcare consumption patterns.

The 4Q 2025 reconstitution of the Morningstar® Wide Moat Focus Index saw selective additions to the Magnificent 7, including NVIDIA and Meta, as AI-driven volatility created valuation opportunities. Despite adding growth-oriented tech names, the Index remains contrarian.

Investors shifted toward selective, fundamentals-driven positioning, favoring companies with clearer execution paths while reassessing crowded or expectation-heavy trades.

Get your portfolio ready for 2026 with detailed insights from VanEck’s investment team about the factors driving risk and returns in their respective asset classes.

Liquidity tightened, Bitcoin signaled early stress, AI adoption gained traction, and real assets continued to lead in a shifting market regime.